Cargando…

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer

SIMPLE SUMMARY: Overactivation of the human epidermal growth factor receptor 2 (HER2) is one of the main drivers of tamoxifen resistance in estrogen receptor (ER)-positive breast cancer patients. Combined targeting of HER2 and ER, however, has yielded disappointing results in the clinical setting. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menendez, Javier A., Papadimitropoulou, Adriana, Vander Steen, Travis, Cuyàs, Elisabet, Oza-Gajera, Bharvi P., Verdura, Sara, Espinoza, Ingrid, Vellon, Luciano, Mehmi, Inderjit, Lupu, Ruth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961649/ https://www.ncbi.nlm.nih.gov/pubmed/33800852 http://dx.doi.org/10.3390/cancers13051132

Ejemplares similares

Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2020)

Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer
por: Papadimitropoulou, Adriana, et al.
Publicado: (2020)

Progesterone receptor isoform-dependent cross-talk between prolactin and fatty acid synthase in breast cancer
por: Menendez, Javier A., et al.
Publicado: (2020)

Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin α(6)β(1) drives endocrine resistance in breast cancer cells
por: Espinoza, Ingrid, et al.
Publicado: (2022)

The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells
por: Menendez, Javier A., et al.
Publicado: (2016)

Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells
por: Schroeder, Barbara, et al.
Publicado: (2021)

Metabolomic and Mitochondrial Fingerprinting of the Epithelial-to-Mesenchymal Transition (EMT) in Non-Tumorigenic and Tumorigenic Human Breast Cells
por: Cuyàs, Elisabet, et al.
Publicado: (2022)

Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
por: Cuyàs, Elisabet, et al.
Publicado: (2020)

Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
por: Verdura, Sara, et al.
Publicado: (2019)

Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology
por: Cuyàs, Elisabet, et al.
Publicado: (2021)

Nutritional Niches of Cancer Therapy-Induced Senescent Cells
por: Llop-Hernández, Àngela, et al.
Publicado: (2022)

Circulating levels of MOTS-c in patients with breast cancer treated with metformin
por: Cuyàs, Elisabet, et al.
Publicado: (2022)

Heregulin, a new interactor of the telosome/shelterin complex in human telomeres
por: Menendez, Javier A., et al.
Publicado: (2015)

The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes
por: Cuyàs, Elisabet, et al.
Publicado: (2020)

Disruption of the ER-α36-EGFR/HER2 Positive Regulatory Loops Restores Tamoxifen Sensitivity in Tamoxifen Resistance Breast Cancer Cells
por: Yin, Li, et al.
Publicado: (2014)

In silico clinical trials for anti-aging therapies
por: Menendez, Javier A., et al.
Publicado: (2019)

Lung Cancer Management with Silibinin: A Historical and Translational Perspective
por: Verdura, Sara, et al.
Publicado: (2021)

Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity
por: Cuyàs, Elisabet, et al.
Publicado: (2017)

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells
por: Verdura, Sara, et al.
Publicado: (2022)

Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based “starvation” strategies in BRCA1 carriers
por: Cuyàs, Elisabet, et al.
Publicado: (2016)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors
por: Verdura, Sara, et al.
Publicado: (2022)

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas
por: Martin-Castillo, Begoña, et al.
Publicado: (2015)

Tamoxifen-Independent Recombination in the RIP-CreER Mouse
por: Liu, Yanmei, et al.
Publicado: (2010)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures
por: Cockburn, Jessica G., et al.
Publicado: (2016)

Suicidality and Illness Course Worsening in a Male Patient with Bipolar Disorder during Tamoxifen Treatment for ER+/HER2+ Breast Cancer
por: Carmassi, Claudia, et al.
Publicado: (2021)

Fatty acid synthase regulates estrogen receptor-α signaling in breast cancer cells
por: Menendez, J A, et al.
Publicado: (2017)

Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity
por: Verdura, Sara, et al.
Publicado: (2020)

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
por: Zboril, Emily K., et al.
Publicado: (2023)

Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer
por: Gu, Yu, et al.
Publicado: (2016)

Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?
por: Menendez, Javier A, et al.
Publicado: (2007)

The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer
por: Cufí, Sílvia, et al.
Publicado: (2013)

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin
por: Bosch-Barrera, Joaquim, et al.
Publicado: (2021)

Tamoxifen-independent Cre-activity in SMMHC-CreER(T2) mice
por: Steffensen, L.B., et al.
Publicado: (2022)

The nutritional phenome of EMT-induced cancer stem-like cells
por: Cuyàs, Elisabet, et al.
Publicado: (2014)

Metformin and breast cancer: an opportunity for pharmacogenetics
por: Cuyàs, Elisabet, et al.
Publicado: (2022)

A unique case of chronic myeloid leukemia presenting as monocular vision loss with unilateral retinopathy
por: Seraly, Mark P., et al.
Publicado: (2019)

Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer
por: Gonzalez-Guerrico, Anatilde M., et al.
Publicado: (2016)

BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells
por: Cuyàs, Elisabet, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_o0cgf96b3ffunpbbch6ptgk3if